Showing results (1-10 of 106) with videos related to
Sort By:
Pageof 11
Journal of Medicinal Chemistry|February 17, 2016
Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and FormaldehydeBenjamin L Barthel, Erin L Mooz, Laura Elizabeth Wiener, et al.Journal of Biopharmaceutical Statistics|July 9, 2008
Cumulative statistical power for hierarchical comparisons to evaluate two combination drug dosesTomoharu Matsukura, Gary G KochJournal of Biopharmaceutical Statistics|May 25, 2010
Multivariate Mann-Whitney estimators for the comparison of two treatments in a three-period crossover study with randomly missing dataAtsushi Kawaguchi, Gary G KochJournal of Biopharmaceutical Statistics|January 8, 2014
An overview of statistical planning to address subgroups in confirmatory clinical trialsGary G Koch, Todd A SchwartzJournal of Biopharmaceutical Statistics|February 11, 2005
Review and evaluation of methods for computing confidence intervals for the ratio of two proportions and considerations for non-inferiority clinical trialsRebekkah S Dann, Gary G KochJournal of Periodontology|March 15, 2018
Statistical Projection of Clinical Subsample Estimates to a Survey PopulationLisa M LaVange, Gary G KochJournal of Biopharmaceutical Statistics|February 27, 2013
Estimating covariate-adjusted log hazard ratios in randomized clinical trials using cox proportional hazards models and nonparametric randomization based analysis of covarianceBenjamin R Saville, Gary G KochPharmaceutical Statistics|May 26, 2007
Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trialsRebekkah S Dann, Gary G KochJournal of Periodontology|August 19, 2007
Statistical projection of clinical subsample estimates to a survey populationLisa M LaVange, Gary G KochArthritis and Rheumatism|April 9, 2005
Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteriaTheodore Pincus, Ingrid Amara, Gary G KochPageof 11